Australian medical technology company LBT Innovations (ASX:LBT) has announced the delivery of its APAS PharmaQC to Thermo Fisher Scientific.
The company said it had delivered an APAS Independence instrument with APAS PharmaQC software to a Thermo Fisher facility, reflecting the positive market interest from pharmaceutical customers following initial market development activities completed in the second half of calendar year 2023, coming approximately six months ahead of previous expectations.
It said it has established a pipeline of potential early adopters interested in the technology.
“The delivery completes the sale of the instrument agreed as part of a strategic development partnership1 with Thermo Fisher, providing funding for the development of APAS PharmaQC to support their culture plate media for use in pharmaceutical microbial quality control applications,” it said.
CEO and managing director Brent Barnes said, “This is an important milestone for the Company, being the first deployment of APAS PharmaQC outside of our partnership with AstraZeneca. The evaluation performed by Thermo Fisher will provide meaningful performance data supporting ‘real world’ use of our technology. This will provide a further third-party validation of APAS PharmaQC and further enhance our commercial activation of the product.”
